Clinical and Laboratory Standards Institute document M23-A3--Development of In Vitro Susceptibility Testing Criteria and
Quality Control Parameters; Approved Guideline--Third Edition offers guidance for developing interpretive criteria and quality
control ranges for antimicrobial susceptibility tests against aerobic and anaerobic bacteria, and yeasts performed by CLSI
antimicrobial susceptibility testing standards. It describes the data utilized by the Antimicrobial Susceptibility Testing and
Antifungal subcommittees to establish these interpretive criteria and QC ranges for antimicrobial agents, including MIC
distributions against relevant microorganisms, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, and clinical
outcome data. As antimicrobial agents are used in practice, additional experience accrued may be used to reassess interpretive
criteria or QC ranges. Users of these guidelines should understand that susceptibility test results cannot predict with absolute
certainty clinical outcomes. They should be used along with the best clinical judgment and laboratory support to draw the best
conclusions serving the patient.
| Number of Pages : | 64 |
| Published : | 01/01/2008 |
